amifostine anhydrous has been researched along with decitabine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cai, LL; Chi, XH; Li, SW; Lu, XC; Ran, HH; Wang, HT; Yang, B; Yang, Y; Yu, RL; Zhao, Y; Zhu, HL | 1 |
1 review(s) available for amifostine anhydrous and decitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for amifostine anhydrous and decitabine
| Article | Year |
|---|---|
Successful management of acute myeloid leukemia transformed from myelodysplastic syndromes in an elderly patient aged over 80 years old by ultralow dose decitabine combined with amifostine and autologous CIK cells.
Topics: Aged, 80 and over; Amifostine; Azacitidine; Cells, Cultured; Combined Modality Therapy; Cytokine-Induced Killer Cells; Decitabine; Disease Management; Disease Progression; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Transplantation, Autologous | 2014 |